Are off-target effects of imatinib the key to improving beta-cell function in diabetes?
The small tyrosine kinase (TK) inhibitor imatinib mesylate (Gleevec, STI571) protects against both type 1 and type 2 diabetes, but as it inhibits many TKs and other proteins, it is not clear by which mechanisms it acts. This present review will focus on the possibility that imatinib acts, at least i...
| Κύριος συγγραφέας: | |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
Upsala Medical Society
2022-09-01
|
| Σειρά: | Upsala Journal of Medical Sciences |
| Θέματα: | |
| Διαθέσιμο Online: | https://ujms.net/index.php/ujms/article/view/8841/14851 |